Increased expression of the NLRP3 inflammasome components in patients with Behçet's disease

Journal of Inflammation (United Kingdom)

Volumn 12, Issue 1, 2015, Pages

  Kim, En Hyung ^a,b   Park, Mi Jin ^a   Park, Sun ^a   Lee, Eun So ^a  

^a Ajou University School of Medicine   (South Korea)

^b Dankook University College of Medicine   (South Korea)

Author keywords

Beh et's disease; Inflammasome; Interleukin 1 ; NLRP3

Indexed keywords

ADENOSINE TRIPHOSPHATE; APOPTOSIS ASSOCIATED SPECK LIKE PROTEIN CONTAINING A CARD; CRYOPYRIN; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; LIPOPOLYSACCHARIDE; MARKER; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ERYTHEMA NODOSUM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; SKIN BIOPSY; SKIN MANIFESTATION;

NEGIBACTERIA;

EID: 84933518359     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/s12950-015-0086-z     Document Type: Article

References (15)

1. Direskeneli H. Autoimmunity vs autoinflammation in Behcet's disease: do we oversimplify a complex disorder? Rheumatology (Oxford). 2006;45:1461-5.
2. Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D. New insights into the pathogenesis of Behcet's disease. Autoimmun Rev. 2012;11:687-98.
3. Yamaguchi Y, Kurita-Ochiai T, Kobayashi R, Suzuki T, Ando T. Activation of the NLRP3 inflammasome in Porphyromonas gingivalis-accelerated atherosclerosis. Pathog Dis. 2015;73:epub. doi: 10.1093/femspd/ftv011.
4. Liang L, Tan X, Zhou Q, Zhu Y, Tian Y, Yu H, et al. IL-1beta triggered by peptidoglycan and lipopolysaccharide through TLR2/4 and ROS-NLRP3 inflammasome-dependent pathways is involved in ocular Behcet's disease. Invest Ophthalmol Vis Sci. 2013;54:402-14.
5. Mitroulis I, Skendros P, Ritis K. Targeting IL-1beta in disease; the expanding role of NLRP3 inflammasome. Eur J Intern Med. 2010;21:157-63.
6. Qiao Y, Wang P, Qi J, Zhang L, Gao C. TLR-induced NF-kappaB activation regulates NLRP3 expression in murine macrophages. FEBS Lett. 2012;586:1022-6.
7. Netea MG, Simon A, van de Veerdonk F, Kullberg BJ, Van der Meer JW, Joosten LA. IL-1beta processing in host defense: beyond the inflammasomes. PLoS Pathog. 2010;6, e1000661.
8. Bauernfeind F, Hornung V. Of inflammasomes and pathogens-sensing of microbes by the inflammasome. EMBO Mol Med. 2013;5:814-26.
9. Gogus F, Fresko I, Elbir Y, Eksioglu-Demiralp E, Direskeneli H. Oxidative burst response to monosodium urate crystals in patients with Behcet's syndrome. Clin Exp Rheumatol. 2005;23 Suppl 38:S81-5.
10. Kaneko F, Oyama N, Nishibu A. Streptococcal infection in the pathogenesis of Behcet's disease and clinical effects of minocycline on the disease symptoms. Yonsei Med J. 1997;38:444-54.
11. Calguneri M, Kiraz S, Ertenli I, Benekli M, Karaarslan Y, Celik I. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behcet's disease. A randomized clinical trial. Arthritis Rheum. 1996;39:2062-5.
12. Do JE, Kwon SY, Park S, Lee ES. Effects of vitamin D on expression of toll-like receptors of monocytes from patients with Behcet's disease. Rheumatology (Oxford). 2008;47:840-8.
13. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519-50.
14. Gul A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, et al. Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study. Ann Rheum Dis. 2012;71:563-6.
15. Keller M, Sollberger G, Beer HD. Thalidomide inhibits activation of caspase-1. J Immunol. 2009;183:5593-9.